# TroFuse-032 (NCT06966700)

> A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06966700
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
- Interventions: Sacituzumab tirumotecan; Pembrolizumab; Rescue Medication; Carboplatin; Paclitaxel; Doxorubicin; Epirubicin; Cyclophosphamide; Capecitabine; Olaparib
- Enrollment: 2400
- Primary outcome: Percentage of Participants with Pathological Complete Response (pCR) at the Time of Definitive Surgery
- Primary outcome: Event-Free Survival (EFS)

## Indexed commentary on TroFuse-032 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 3
- X threads: 3
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=trofuse-032-nct06966700

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06966700", "email": "<work email>"}; the inbox owner confirms by the emailed link.